Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients hospitalized due to acute decompensated HF episode (ADHF) as primary diagnosis) and consistent Signs \& Symptoms~2. Diagnosis of HF New York Heart Association class II-to-IV and reduced ejection fraction: Left ventricular ejection fraction ≤ 40% at Screening~3. Patients did not receive any IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for ADHF to Randomization~4. Stabilized (while in the hospital) for at least 24 hours leading to Randomization.~5. Meeting one of the following criteria:~   * Patients on any dose of ACEI or ARB at screening~  * ACEI/ARB naïve patients and patients not on ACEI or ARB for at least 4 weeks before screening.~Exclusion Criteria:~1. History of hypersensitivity to the sacubitril, valsartan, or any ARBs, NEP inhibitors or to any of the LCZ696 excipients.~2. Symptomatic hypotension and/or a SBP below 110 mm Hg or SBP above 180 mm Hg prior to randomization~3. End stage renal disease at Screening; or estimated GFR below 30 mL/min/1.73 m2 (as measured by MDRD formula at Randomization.~4. Serum potassium above 5.4 mmol/L at Randomization.~5. Known history of hereditary or idiopathic angioedema or angioedema related to previous ACE inhibitor or ARB therapy~6. Severe hepatic impairment, biliary cirrhosis and cholestasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-discharge treatment initiation (Type: OTHER): Patients received first dose at any point after Randomization but no later than 12 h before discharge.
- Post-discharge treatment initiation (Type: OTHER): Patients received first dose after discharge and up to 14 days thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).